In non-immunised patients, one should start with the PCV13
, then wait for 2 months, and thereafter administer the PPSV23 vaccine.
Recently, the ACIP recommended routine administration of both PCV13
and PPSV23 to all adults [greater than or equal to] 65 years of age (5).
(Prevenar13[R]) has been licensed in New Zealand for adults over 50 years, but there are currently no clear recommendations for use in this age group, although it can be recommended for those at higher risk of pneumococcal disease, eg those with chronic lung diseases.
4) US researchers conducted a new study to see if a new vaccine, PCV13
, stimulates an immune system response in HIV-positive adults already vaccinated with PPSV23.
Conjugate vaccine p / children~s pneumococcal vaccine PCV13
compatible with - to continue vaccination in the number of 95 800 doses.
vaccine's efficacy in adults aged 65 years and older has never been determined until now It became possible to assess efficacy in this age group when a serotype-specific urinary antigen detection assay was developed, which can identify Streptococcus pneumonia polysaccharides in the urine of patients suspected of having pneumonia rather than requiring isolation of the organism in culture, said Dr.
If a person has already received a PPSV23 dose, the PCV13
immunization should be given at least one year after receiving the prior pneumococcal vaccine.
The other is pneumococcal conjugate vaccine, PCV13
(brand name Prevnar 13), which is routinely given to infants and toddlers, but was approved by the FDA in 2011 for use in adults 50 and older.
Revised immunization guidelines for older adults to reflect new recommendations by the Centers for Disease Control and Prevention that people age 65 or older who have not received a pneumonia vaccine receive two separate shots, PCV13
(Prevnar), followed 12 months later by PPSV23 (Pneumovax).
It is also recommended that those who have a cochlear implant and who have received PPSV23 should still get the PCV13
Pneumococcal Vaccine PPV23 for Adults and PCV13
Each dose of the new pneumococcal vaccine, PCV13
, costs less than a cup of coffee.